GlassScriptPhysician profile
David O Kovacich
NPI 1447221981
$326,870.52
in general payments reported to CMS, 2019-2025
27 companies · $9,566 in 2025
The $9,566 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $29K · 2021: $12K · 2022: $59K · 2023: $51K · 2024: $20K · 2025: $9,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $5,259 · Travel and Lodging: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,685.00 |
| Food and Beverage | $5,258.87 |
| Travel and Lodging | $1,385.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $141,014.09 | 2019-2024 | Xarelto |
| Amgen INC. | $88,626.30 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $69,908.36 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $23,743.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $985.65 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Pfizer INC. | $446.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $337.60 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $241.42 | 2023-2025 | Wegovy, Ozempic |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Esperion Therapeutics, INC. | $182.54 | 2022-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $177.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.83 | 2021-2025 | Jardiance |
| Edwards Lifesciences Corporation | $139.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $109.25 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $109.09 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $78.21 | 2024 | Arcalyst |
| Boston Scientific Corporation | $50.45 | 2019-2024 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $46.61 | 2023-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $46.53 | 2023-2025 | Opsumit, Uptravi |
| Medtronic, INC. | $44.45 | 2024 | Micra |
| Impulse Dynamics (USA) INC. | $28.70 | 2022 | |
| Bridgebio Pharma, INC. | $18.35 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $17.50 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $14.69 | 2025 | |
| Abbott Laboratories | $14.60 | 2024 | Mitraclip |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kovacich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.